SCHEMBL564423

SCHEMBL564423

CC(C)CN(Cc1cc(Cl)c2c(c1)OCCCO2)C(=O)[C@@H]1CCN(Cc2cccc([N+](=O)[O-])c2)C1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 5/20 0.66
ALDH1A1 P00352 5/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 7/20 0.39
MAPK1 P28482 3/20 0.39
POLB P06746 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
HTT P42858 1/20 0.38
CHRM5 P08912 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL565653 0.96 PROKR2 (0.67) PROKR2ALDH1A1L3MBTL1KDM4EMAPK1
SCHEMBL10106776 0.96 PROKR2 (0.67) PROKR2ALDH1A1L3MBTL1KDM4EMAPK1
SCHEMBL565506 0.93 PROKR2 (0.66) PROKR2ALDH1A1KDM4EMAPK1POLB
SCHEMBL565449 0.93 PROKR2 (0.64) PROKR2ALDH1A1KDM4EMAPK1POLB
SCHEMBL10107192 0.93 PROKR2 (0.64) PROKR2ALDH1A1KDM4EMAPK1POLB
SCHEMBL564923 0.90 PROKR2 (0.71) PROKR2ALDH1A1L3MBTL1KDM4ESMN1; SMN2
SCHEMBL565426 0.90 PROKR2 (0.73) PROKR2ALDH1A1KDM4EPOLBSMN1; SMN2
SCHEMBL565136 0.90 PROKR2 (0.73) PROKR2ALDH1A1KDM4EPOLBSMN1; SMN2
SCHEMBL565369 0.89 PROKR2 (0.70) PROKR2ALDH1A1KDM4EPOLBKMT2A
SCHEMBL10107242 0.89 PROKR2 (0.70) PROKR2ALDH1A1KDM4EPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof PROKR2, PROKR1, GIPR PROKR2 1/4885ALDH1A1 4725/4885L3MBTL1 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.